GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: AMG-477 | AMG477 | REMD-477 | REMD477
Compound class:
Antibody
Comment: Volagidemab (REMD-477) is a fully human anti-glucagon receptor monoclonal antibody. It acts as an antagonist of receptor function.
Based on peptide sequence matches for antibody heavy and light chains between the INN record and patent US7947809B2, volagidemab appears to be clone A-4 therein [3]. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Pettus J, Boeder SC, Christiansen MP, Denham DS, Bailey TS, Akturk HK, Klaff LJ, Rosenstock J, Cheng MHM, Bode BW et al.. (2022)
Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial. Nat Med, 28 (10): 2092-2099. [PMID:36192552] |
|
2. Pettus J, Reeds D, Cavaiola TS, Boeder S, Levin M, Tobin G, Cava E, Thai D, Shi J, Yan H et al.. (2018)
Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial. Diabetes Obes Metab, 20 (5): 1302-1305. [PMID:29283470] |
|
3. Yan H, Hu SFS, Boone TC, Lindberg RA. (2011)
Compositions and methods relating to glucagon receptor antibodies. Patent number: US7947809B2. Assignee: Amgen Inc. Priority date: 20/09/2007. Publication date: 24/05/2011. |
